Investors Alerted by Levi & Korsinsky on Regeneron Class Action Deadline

Overview

The law firm Levi & Korsinsky, LLP has sent out an urgent reminder to investors of Regeneron Pharmaceuticals, Inc. regarding a pending securities class action. This legal action is significant for shareholders who acquired Regeneron securities between August 1, 2025, and May 15, 2026. As per the announcement, investors have until September 14, 2026, to apply as a lead plaintiff.

Background of the Case

Regeneron Pharmaceuticals, listed on NASDAQ under the symbol REGN, has faced scrutiny following a marked decline in its stock value. Specifically, the shares fell from $731.77 on April 28, 2026, down to $629.68 after the company made a disclosure about a clinical trial on May 15, 2026, indicating that the Phase III Fianlimab-Libtayo Study did not deliver the expected statistical significance regarding its primary endpoint. This decline equates to a drop of $102.09 per share, approximately a 13.95% decrease, raising concerns among investors regarding the company’s disclosures and the management's accountability for public statements.

Allegations of Control Person Liability

The allegations center around the actions of Regeneron executives, notably Co-Founder and CEO George D. Yancopoulos, along with other senior officials. The complaint suggests that these individuals had substantial authority over critical disclosures made to the public, particularly concerning clinical-trial results that investors relied upon.

As outlined in the complaint, the defendants are accused of having non-public information that may have been significant in shaping the company's communications to investors and analysts about their clinical trials. They allegedly conveyed an overly favorable picture of the trial outcomes while neglecting to mention the potential risks that might adversely affect the trial's success.

Key Events and Investor Concerns

Concerns heightened following changes made to the trial protocol just prior to the May announcement, expanding the criteria for patients eligible for the progression-free survival (PFS) analysis. Investors grew wary that such changes indicated potential shortcomings or flaws in the company's assumptions regarding the trial's design. The impact of this on Regeneron's stock value was stark and led to the current legal actions.

Importance of Accountability for Investors

This case speaks to broader issues of leadership accountability within pharmaceutical companies. It highlights the critical need for corporate executives to provide accurate and complete information, particularly when it pertains to clinical trials that have the potential to significantly impact stock prices and investor trust. Investors in Regeneron are reminded that they may qualify for recovery if they suffered losses during the class period in question. Legal avenues are available for those affected, and claims must be filed by the specified deadline.

Conclusion

Investors of Regeneron Pharmaceuticals are urged to carefully review their transaction history and consult with financial or legal advisors regarding their eligibility in this class action. The May 15 announcement's implications could prove costly for many, and taking timely action could help stakeholders mitigate their losses. Levi & Korsinsky remains committed to representing shareholders in this matter, ensuring that those impacted have all available remedies accessible to them.

For further inquiries or to participate in the class action, affected investors can contact Joseph E. Levi, Esq. at [email protected] or call (212) 363-7500.